Antares Pharma Inc.

Antares Pharma Inc. company information, Employees & Contact Information

About Antares Antares Pharma is a specialty pharmaceutical company that combines drug development expertise with proprietary delivery technology to deliver safe and effective medicines. With a goal of improving dosing, reducing side effects, and improving patient compliance and outcomes, our pursuit of innovative therapies strives to positively affects patients’ lives. We focus on self-injection, pharmaceutical products and technologies with emphasis in rheumatology, urology, endocrinology, and neurology. Through innovation, Antares Pharma combines pharmaceutical and medical device knowledge to produce treatment options that best serve our patients, physicians, partners, and stakeholders. Our Mission We at Antares Pharma leverage our pharmaceutical and medical device expertise to develop innovative products that address needs in underserved therapeutic areas. Our relentless pursuit of better therapies that positively affect patient lives inspires our employees to serve our customers and stakeholders every day.

Company Details

Employees
67
Address
100 Princeton South,
Phone
7634761009
Email
jh****@****rma.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Ewing, NJ
Looking for a particular Antares Pharma Inc. employee's phone or email?

Antares Pharma Inc. Questions

News

Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader - PR Newswire

Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader PR Newswire

Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue - GlobeNewswire

Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue GlobeNewswire

Antares Pharma develops novel auto-injector devices for innovative combination products - Fierce Pharma

Antares Pharma develops novel auto-injector devices for innovative combination products Fierce Pharma

Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue - Stock Titan

Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue Stock Titan

New Products: Cuff stops urinary leakages in PCa patients - Urology Times

New Products: Cuff stops urinary leakages in PCa patients Urology Times

HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS - PR Newswire

HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS PR Newswire

Company Hopes to Deliver 'Virtually Painless Treatment Experience' with QuickShot Testosterone - Medical Professionals Reference

Company Hopes to Deliver 'Virtually Painless Treatment Experience' with QuickShot Testosterone Medical Professionals Reference

Antares Pharma (ATRS) Stock Price, News & Analysis - MarketBeat

Antares Pharma (ATRS) Stock Price, News & Analysis MarketBeat

Antares Pharma Announces Divestiture of Otrexup® - GlobeNewswire

Antares Pharma Announces Divestiture of Otrexup® GlobeNewswire

J&J, Roche partner Halozyme buys Antares Pharma for $1B, beefing up drug delivery offerings - Fierce Pharma

J&J, Roche partner Halozyme buys Antares Pharma for $1B, beefing up drug delivery offerings Fierce Pharma

Halozyme to Present at Upcoming Investor Conferences - Stock Titan

Halozyme to Present at Upcoming Investor Conferences Stock Titan

New Testosterone Replacement Therapy Approved for At-Home Self-Administration - Medical Professionals Reference

New Testosterone Replacement Therapy Approved for At-Home Self-Administration Medical Professionals Reference

Antares Pharma Announces FDA Approval of Generic EpiPen Utilizing VIBEX Auto Injector - GlobeNewswire

Antares Pharma Announces FDA Approval of Generic EpiPen Utilizing VIBEX Auto Injector GlobeNewswire

HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA - PR Newswire

HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA PR Newswire

Halozyme Completes Antares Pharma Acquisition - PR Newswire

Halozyme Completes Antares Pharma Acquisition PR Newswire

Antares Receives FDA Approval of Xyosted™ (Testosterone - GlobeNewswire

Antares Receives FDA Approval of Xyosted™ (Testosterone GlobeNewswire

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis - PR Newswire

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis PR Newswire

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE - PR Newswire

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE PR Newswire

Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2028 - PR Newswire

Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2028 PR Newswire

Watson and Antares Announce the Introduction of Gelnique 3%™, for the Treatment of Overactive Bladder - PR Newswire

Watson and Antares Announce the Introduction of Gelnique 3%™, for the Treatment of Overactive Bladder PR Newswire

Top Antares Pharma Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant